# OnCo record pegilodecakin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pegilodecakin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "pegilodecakin" ;
  schema:name "Pegilodecakin"@en ;
  schema:alternateName "AM0010"@en, "Pegylated interleukin-10"@en ;
  schema:description "Pegilodecakin, a long-acting interleukin-10 meant to expand tumour-killing T cells, added nothing to FOLFOX in the phase 3 SEQUOIA trial of second-line pancreatic cancer, and Eli Lilly dropped it."@en ;
  schema:url <https://onco.cc/drugs/pegilodecakin/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.20.02232>, <https://clinicaltrials.gov/study/NCT02923921> ;
  onco:status "negative" ;
  onco:modality "PEGylated recombinant human interleukin-10 (cytokine)" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:terms <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/pancreatic-failed-programmes/> ;
  onco:trials <https://onco.cc/trials/sequoia/> .